Completed PHASE4 INTERVENTIONAL 3-arm NCT01851590

Resin vs. Amorolfine vs. Terbinafine Treatment in Onychomycosis

Efficacy of Topical Resin Lacquer, Amorolfine, and Oral Terbinafine for Treating Toenail Onychomycosis: a Prospective, Randomized, Controlled, Investigator-blinded, Parallel-group Clinical Trial

Sponsor: Helsinki University Central Hospital

Conditions Onychomycosis

Interventions Amorolfine Resin Lacquer Terbinafine

Updated 10 times since 2017 Last updated: Oct 24, 2015 Started: Oct 31, 2013 Primary completion: Oct 31, 2014 Completion: Oct 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01851590, this PHASE4 trial focuses on Onychomycosis and remains completed. Sponsored by Helsinki University Central Hospital, it has been updated 10 times since 2013, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

10 versions recorded

Feb 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Feb 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Dec 2021 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Dec 2021 [monthly]

Completed PHASE4

▶ Show 5 earlier versions

Nov 2020 — Jan 2021 [monthly]

Completed PHASE4
Jun 2018 — Nov 2020 [monthly]

Completed PHASE4
May 2018 — Jun 2018 [monthly]

Completed PHASE4
Aug 2017 — May 2018 [monthly]

Completed PHASE4
Jan 2017 — Aug 2017 [monthly]

Completed PHASE4

First recorded

Oct 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Helsinki University Central Hospital
Repolar Pharmaceuticals Oy

Data source: Helsinki University Central Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Vääksy, Finland